|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Furthermore, EHT 1864 inhibited estrogen-induced cell proliferation in breast cancer cells and decreased tamoxifen-resistant breast cancer cell growth.
|
21118977 |
2011 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Overall, our data indicate that the p85 subunit is a valid target for therapeutic approaches and suggest that the structure of the peptide used in our study could be utilized for the development of novel drugs to apply in combination with therapies that fail to cure BCs with high PI3K activity.
|
23222510 |
2012 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrate that a formulation containing the block copolymer Pluronic P85 and antineoplastic drug doxorubicin (Dox) prevents the development of multidrug resistance in the human breast carcinoma cell line, MCF7.
|
16579640 |
2006 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
|
28027535 |
2017 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Furthermore, EHT 1864 inhibited estrogen-induced cell proliferation in breast cancer cells and decreased tamoxifen-resistant breast cancer cell growth.
|
21118977 |
2011 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Overall, our data indicate that the p85 subunit is a valid target for therapeutic approaches and suggest that the structure of the peptide used in our study could be utilized for the development of novel drugs to apply in combination with therapies that fail to cure BCs with high PI3K activity.
|
23222510 |
2012 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
|
28027535 |
2017 |
|
Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Correction to: CBFA2T2 is associated with a cancer stem cell state in renal cell carcinoma.
|
29782581 |
2018 |
|
Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In the current study, anticancer activity of a novel heterodinuclear Cu(II)-Mn(II) complex (Schiff base-SB) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (pluronic) P85 was tested against RCC.
|
29288416 |
2018 |
|
Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our data suggest that CBFA2T2 expression correlates with aggressive characteristics of RCC and CBFA2T2 is required for maintenance of "stemness" through regulation of stem cells factors, thereby highlighting CBFA2T2 as a potential therapeutic target for RCC treatment.
|
29162985 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our data suggest that CBFA2T2 expression correlates with aggressive characteristics of RCC and CBFA2T2 is required for maintenance of "stemness" through regulation of stem cells factors, thereby highlighting CBFA2T2 as a potential therapeutic target for RCC treatment.
|
29162985 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In the current study, anticancer activity of a novel heterodinuclear Cu(II)-Mn(II) complex (Schiff base-SB) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (pluronic) P85 was tested against RCC.
|
29288416 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Correction to: CBFA2T2 is associated with a cancer stem cell state in renal cell carcinoma.
|
29782581 |
2018 |
|
Malignant neoplasm of prostate
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells.
|
31428587 |
2019 |
|
Malignant neoplasm of prostate
|
0.030 |
Biomarker
|
disease |
BEFREE |
This is the first study presenting the anti-cancer activity of the present Schiff base derivative and its combination with P85 to treat prostate cancer in vitro.
|
28012929 |
2017 |
|
Malignant neoplasm of prostate
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In the current study, a novel heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used to evaluate anticancer activity against prostate cancer in vitro and in vivo.
|
28614092 |
2017 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells.
|
31428587 |
2019 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
This is the first study presenting the anti-cancer activity of the present Schiff base derivative and its combination with P85 to treat prostate cancer in vitro.
|
28012929 |
2017 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In the current study, a novel heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used to evaluate anticancer activity against prostate cancer in vitro and in vivo.
|
28614092 |
2017 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, in human colorectal cancer (CRC) samples MTGR1 was downregulated at both the transcript and protein level.
|
27270437 |
2016 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
DC-SIGN activation recruited Lyn and p85 to form the DC-SIGN-Lyn-p85 complex, which promoted CRC metastasis by increasing PI3K/Akt/β-catenin signaling in tyrosine kinase Lyn-dependent manner.
|
31217502 |
2020 |
|
Hepatitis C
|
0.020 |
Biomarker
|
disease |
BEFREE |
Notably, p85 and p110 are competed out for their binding to HCV 5' UTR when excess amounts of iron-responsive element (IRE) competitor RNAs are treated.
|
18566883 |
2008 |
|
Hepatitis C
|
0.020 |
Biomarker
|
disease |
BEFREE |
In this regard, we showed previously that the HCV NS5A protein bound to the p85 regulatory subunit of phosphoinositide-3 kinase (PI3K), thereby stimulating the activity of the p110 catalytic subunit of the enzyme.
|
19846673 |
2010 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
Biomarker
|
disease |
BEFREE |
Monocytic MLL-AF9 expressing cells (MM6, THP-1) were hypersensitive to both small-molecule inhibitors targeting Rac1 (EHT 1864, NSC 23766) (IC50EHT ~12.5 μM) and lipid lowering drugs (lovastatin, atorvastatin) (IC50Lova ~7.5 μM) as compared to acute myelocytic leukemia (NOMO-1, HL60) and T cell leukemia (Jurkat) cells (IC50EHT >30 μM; IC50Lova >25 μM).
|
23624644 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Among them CBFA2T2, a member of the "ETO" family, is known because of its homology and association with the product of RUNX1-CBFA2T1 gene fusion generated by t(8;21) translocation, one frequent cause of acute myeloid leukemia.
|
20958258 |
2011 |